Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Patient Navigation Models for Lung Cancer

Patient Navigation Models for Lung Cancer Rapid Evidence Product Patient Navigation Models for Lung Cancer eRapid Evidence Product Patient Navigation Models for Lung Cancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2017-00003-C Prepared by: Scientific Resource Center Portland, OR Investigators: Jennifer Gilbert, M.D., M.P.H. Stephanie Veazie, M.P.H. Kevin Joines, B.S (...) , other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Gilbert J, Veazie S, Joines K, Winchell K, Relevo R, Paynter R, Guise J-M. Patient Navigation Models for Lung Cancer. Rapid Evidence Product. (Prepared by Scientific Resource Center under Contract No. 290-2017-00003-C.) AHRQ Publication No. 18(19

Effective Health Care Program (AHRQ)2018

2. Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer Drug Approval Package: LORBRENA (lorlatinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LORBRENA (lorlatinib) Company: Pfizer, Inc. Application Number: 210868 Approval Date: 11/02/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter

FDA - Drug Approval Package2018

3. Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC)

Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/674777/2018 EMEA/H/C/004248 Alunbrig (brigatinib) An overview of Alunbrig and why it is authorised in the EU What (...) is Alunbrig and what is it used for? Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) who have been treated before with a cancer medicine called crizotinib. Alunbrig is used on its own and only if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain changes affecting the gene that makes a protein called ALK (anaplastic lymphoma kinase). Alunbrig contains the active substance brigatinib. How is Alunbrig

European Medicines Agency - EPARs2018

4. Delivering best practice lung cancer care - a guide for health professionals

Delivering best practice lung cancer care - a guide for health professionals This guide provides an overview of the Lung Cancer Framework, which can be accessed at: canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/lung-cancer-framework A summary for health professionals Delivering best practice lung cancer care Cancer Australia’s Lung Cancer Framework: Principles for Best Practice Lung Cancer Care in Australia (the Lung Cancer Framework) is a national resource (...) for health professionals and service providers involved in the care and treatment of people affected by lung cancer. canceraustralia.gov.au The Lung Cancer Framework aims to improve the outcomes and experiences of people affected by lung cancer in Australia by supporting the uptake of five key principles in lung cancer care. Principles for best practice lung cancer care Cancer Australia’s Principles for best practice management of lung cancer in Australia have been informed by evidence from national

Cancer Australia2018

5. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation

Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search (...) above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Low-dose CT screening may be effective in reducing lung cancer mortality, but there is considerable uncertainty around effectiveness and value. {{author}} {{($index , , , , , , & . Tristan Snowsill 1, * , Huiqin Yang 1 , Ed Griffin 1 , Linda Long 1 , Jo Varley-Campbell 1 , Helen Coelho 1 , Sophie Robinson 1 , Chris Hyde 1, 2 1 Peninsula Technology Assessment

NIHR HTA programme2018

8. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial 30262574 2018 10 05 1399-3003 52 4 2018 Oct The European respiratory journal Eur. Respir. J. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. 1801220 10.1183/13993003.01220-2018 The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant (...) low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous tinzaparin 100 IU·kg -1 once a day for 12 weeks or no treatment in addition to standard of care. The trial was open-label with blinded central adjudication of study outcomes. The primary outcome was overall survival.In 549 patients randomised to tinzaparin (n=269

EvidenceUpdates2018

9. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer 30153097 2018 08 28 1527-7755 2018 Aug 28 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell (...) Lung Cancer. JCO2018783118 10.1200/JCO.2018.78.3118 Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned to osimertinib or standard EGFR-TKIs (gefitinib or erlotinib); brain scans were not mandated unless clinically indicated. Patients

EvidenceUpdates2018

11. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 30262187 2018 09 28 1474-5488 2018 Sep 21 The Lancet. Oncology Lancet Oncol. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. S1470-2045(18)30673-9 10.1016/S1470-2045(18)30673-9 Antibodies targeting the immune checkpoint molecules PD (...) -1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy. JAVELIN Lung 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC

EvidenceUpdates2018

14. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report

Screening for Lung Cancer: CHEST Guideline and Expert Panel Report Screening for Lung Cancer CHEST Guideline and Expert Panel Report Peter J. Mazzone, MD, MPH, FCCP; Gerard A. Silvestri, MD, FCCP; Sheena Patel, MPH; Jeffrey P. Kanne, MD, FCCP; Linda S. Kinsinger, MD; Renda Soylemez Wiener, MD, MPH; Guy Soo Hoo, MD, FCCP; and Frank C. Detterbeck, MD, FCCP BACKGROUND: Low-dose chest CTscreening for lung cancer has becomeastandard ofcare in the United States in the past few years, in large part (...) addressed resulting in six graded recommendations and nine ungraded consensus based statements. CONCLUSIONS: Evidence suggests that low-dose CT screening for lung cancer results in a favorable but tenuous balance of bene?t and harms. The selection of screen-eligible patients, thequalityofimagingandimageinterpretation,themanagementofscreen-detected?ndings, and the effectiveness of smoking cessation interventions can affect this balance. Additional research is needed to optimize the approach to low-dose

American College of Chest Physicians2018

15. Whole brain radiotherapy provides little benefit for lung cancer that has spread

Whole brain radiotherapy provides little benefit for lung cancer that has spread Signal - Whole brain radiotherapy provides little benefit for lung cancer that has spread Dissemination Centre Discover Portal NIHR DC Discover Whole brain radiotherapy provides little benefit for lung cancer that has spread Published on 10 January 2017 Radiotherapy to the whole brain makes little difference to people with the commonest type of lung cancer that has spread to the brain and cannot be operated (...) on. This mainly UK-based trial found no difference in overall survival and quality of life among people who had whole brain radiotherapy plus usual supportive care compared with people who received supportive care alone. This is the largest trial to assess the effect of this treatment in people with non-small cell lung cancer and multiple brain metastases (cancer deposits in the brain). Practice has been changing since early results of the trial were released. The final results reinforce the message

NIHR Dissemination Centre2018

16. Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer

Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Signal - Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Dissemination Centre Discover Portal NIHR DC Discover Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Published on 28 February 2017 Postoperative radiotherapy increases the risk of death by 18% for patients with non-small cell lung cancer that has been (...) on survival and cancer recurrence rates. Most of the trials are from over 30 years ago, so there is the possibility that newer radiotherapy techniques may be less harmful. Nevertheless, this review provides the best evidence to date that postoperative radiotherapy may not be appropriate as a routine treatment for non-small cell lung cancer. Share your views on the research. Why was this study needed? Lung cancer is the second most common cancer in the UK with 37,453 new cases registered in 2014

NIHR Dissemination Centre2018

17. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach.

Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Background: Tobacco control efforts implemented in the United States since the 1960s have led to considerable reductions in smoking and smoking-related diseases, including lung cancer. Objective: To project reductions in tobacco use and lung cancer mortality from 2015 to 2065 due to existing tobacco control efforts. Design: Comparative modeling approach using 4 simulation models (...) of the natural history of lung cancer that explicitly relate temporal smoking patterns to lung cancer rates. Setting: U.S. population, 1964 to 2065. Participants: Adults aged 30 to 84 years. Measurements: Models were developed using U.S. data on smoking (1964 to 2015) and lung cancer mortality (1969 to 2010). Each model projected lung cancer mortality by smoking status under the assumption that current decreases in smoking would continue into the future (status quo trends). Sensitivity analyses examined

Annals of Internal Medicine2018

18. Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study

Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study 29758181 2018 09 09 1931-3543 154 3 2018 Sep Chest Chest Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study. 501-511 S0012-3692(18 (...) )30731-1 10.1016/j.chest.2018.04.040 There is currently no consensus regarding the optimal postoperative follow-up strategy for patients with completely resected non-small cell lung cancer (NSCLC). We aimed to develop web-based nomograms to precisely predict site-specific postoperative recurrence in patients with NSCLC and to guide individual surveillance strategies including when to follow up and what diagnostic tests to perform. We investigated the pattern of recurrence in a series of 2,017

EvidenceUpdates2018

20. Gefitinib Mylan - non-small cell lung cancer

Gefitinib Mylan - non-small cell lung cancer Gefitinib Mylan | European Medicines Agency Search Search Menu Gefitinib Mylan gefitinib Table of contents Authorised This medicine is authorised for use in the European Union. Overview Gefitinib Mylan is a cancer medicine used to treat adults who have non-small cell lung cancer that is locally advanced or metastatic (when cancer cells have spread from the original site to other parts of the body). It is used in patients whose cancer cells have (...) on the surface of cancer cells, such as EGFR on the surface of non-small cell lung cancer cells. EGFR is involved in the growth and spread of cancer cells. By blocking EGFR, Gefitinib Mylan helps to slow down the growth and spread of the cancer. Gefitinib Mylan works only in non-small cell lung cancer cells that have a mutation in their EGFR. How has Gefitinib Mylan been studied? Studies on the benefits and risks of the in the authorised use have already been carried out with the reference medicine, Iressa

European Medicines Agency - EPARs2018